Searchable abstracts of presentations at key conferences in endocrinology

ea0026p250 | Pituitary | ECE2011

Evolution of invasive treatment-resistant prolactin (PRL) adenoma

Vetri M , Tita P

Giant prolactinomas are rare and their treatment and outcome has been addressed only in isolated case reports. Some patients develop treatment-resistant tumors. We describe a patient with an invasive PRLoma resistant to conventional therapy. A 40-year-old female was diagnosed at age 22 a PRLoma who, although having received all available formulations of dopamine agonists over a period of 18 years, responded neither clinically, nor hormonally (PRL 9560.0 ng/ml, nv <20). At ...

ea0026p254 | Pituitary | ECE2011

Lack of efficacy of 24-month treatment with the GH receptor antagonist pegvisomant in patient with active acromegaly resistant to long-term, high-dose somatostatin analog treatment: effects on IGF1 and GH levels

Vetri M , Tita P

In acromegaly symptom control can be achieved by lowering insulin-like growth factor 1 (IGF1) concentrations to the age-adjusted normal range. However, even with optimal surgery and current medical therapies (dopamine agonists, somatostatin analogues), 30–50% of patients do not achieve target concentrations of IGF1 and GH. Pegvisomant (PEGV), a new GH-receptor antagonist, given as s.c. injections at variable dosages, could normalises IGF1 concentrations in ~70% of acromeg...

ea0026p145 | Male reproduction | ECE2011

Criptorchidism, varicocele, azoospermia and Leydig cell tumor in a couple of identical twins with a unique de novo balanced reciprocal translocation.

Vetri M , Stancampiano A , Licciardello L

Chromosomal translocations or inversions, may cause spermatogenic failure. We present a case of a 35-years-old couple of identical twins: GD and GS. Both had criptorchidism and bilateral varicocele and underwent medical treatment first, and orchipexy and varicocelectomy subsequently at 7 years and 28 years respectively. GD at 31 years had left orchiectomy because of Leydig cell tumor. They were referred to our clinic for azoospermia and fatherhood desire. The patients were a n...

ea0026p147 | Male reproduction | ECE2011

Efficacy of recombinant human follicle-stimulating hormone (rhFSH) in the treatment of male-factor infertility.

Vetri M , Stancampiano A , Crimi S

To study the efficacy of rhFSH treatment on male infertility we evaluated the response of 79 hypo-normogonadotrophic patients referring to our clinic for couple infertility after a period of not <12–18 months of finalized unprotected intercourse without conception. rhFSH 150 IU were given subcutaneously every other day for 12 months (mean 15±3 months). All men, between 23 and 56 years (mean 34±8 years), were divided into three subgroups: i) hypogonadotropic ...

ea0026p627 | Clinical case reports | ECE2011

Clinical, hormonal and cytogenetic evaluation of 46,XX male

Vetri M , Stancampiano A , Licciardello L

The XX male syndrome, also called ‘de la Chapelle syndrome’, has been renamed as ‘46, XX testicular disorder of sex development’ (DSD) in 2006. It occurs in about 1/20 000 male newborns. We describe a 57-years-old male who referred to our andrological outpatient clinic because of erectile dysfunction. He was a smoker and suffered from 15 years of type 2 diabetes mellitus; he was also carrying a euthyroid multinodular goiter. The physical examination include...